BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report.

Area of Science:

• Oncology
• Genetics
• Molecular Diagnostics

Background:

• High-grade serous ovarian carcinoma (HGSOC) is the most prevalent ovarian cancer subtype.
• Sensitivity to poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) in HGSOC is linked to BRCA1/2 mutations.
• Accurate detection of BRCA1/2 mutations is critical for guiding PARPi-based treatment strategies.

Purpose of the Study:

• To evaluate the diagnostic utility of next-generation sequencing (NGS) for detecting BRCA1/2 mutations in HGSOC patients.
• To assess the frequency of pathogenic BRCA1/2 alterations in a cohort of HGSOC cases.

Main Methods:

• Retrospective analysis of BRCA1/2 next-generation sequencing (NGS) data from 65 HGSOC patients (January 2020 - September 2021).
• Utilized the Ion S5™ System with the Oncomine™ BRCA Research Assay for molecular analysis.
• Classified variants as pathogenic or likely pathogenic using American College of Medical Genetics and Genomics guidelines, ENIGMA, and ClinVar databases.

Main Results:

• NGS analysis successfully evaluated 65 HGSOC patient samples.
• Pathogenic alterations in BRCA1/2 were identified in 11 cases (16.9%), comprising six BRCA1 and five BRCA2 variations.
• The study demonstrated high sensitivity and efficiency of NGS in detecting clinically relevant BRCA1/2 mutations.

Conclusions:

• Next-generation sequencing (NGS) is a highly sensitive and efficient method for identifying BRCA1/2 mutations in high-grade serous ovarian carcinoma (HGSOC).
• This molecular profiling is essential for patient selection for targeted poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) therapy.